Gossamer Bio (NASDAQ:GOSS) reported top-line results from PROSERA, its global phase III registrational study evaluating ...

By Sahil Pandey and Siddhi Mahatole Feb 23 (Reuters) - Gossamer Bio's experimental treatment failed to significantly improve ...

Gossamer Bio Inc. GOSS dropped during early trading on Monday after the company shared topline results from the Phase 3 PROSERA study evaluating seralutinib in pulmonary arterial hypertension. PAH is ...

Gossamer Bio's phase three study of its seralutinib drug for Pulmonary Arterial Hypertension did not meet the statistical threshold for its primary endpoint. Shares fell 82% to 38 cents in premarket ...

Belite Bio's lead drug, Tinlarebant, shows promise in rare eye diseases, but pivotal data and regulatory approval remain at least 18 months away in my view. The DRAGON study's interim analysis is ...

Gossamer Bio Inc. (NASDAQ:GOSS) is one of the best biotech stocks to invest in now. On June 16, Gossamer Bio announced the completion of enrollment for its global registrational Phase 3 PROSERA Study.

BOSTON--(BUSINESS WIRE)--Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today ...

Nitrogen is often the most limiting factor when it comes to crop productivity. A recent three-year study concluded that Pivot Bio’s microbial products effectively deliver nitrogen while delivering ...

A demonstrated 100% concordance between biomarker-guided predictions from pre-treatment patient samples and clinical outcomes ...

PB-001, also referred to as the PVEK corneal implant, is a first-in-class 3D-printed tissue made from corneal endothelial cells. It is designed to open and assume a natural corneal shape during ...

The last time I spoke about Upstream Bio, Inc. (UPB) it was in a Seeking Alpha article entitled "Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation." With respect to this ...